IP Library Granted Patent US 9,222,092
Granted Patent B2
US 9,222,092 · App. 14/578,636 · Granted Dec 29, 2015

Interfering RNA molecules

Inventors: Klaus Giese (Berlin, DE); Jörg Kaufmann (Berlin, DE); Anke Klippel-Giese (Berlin, DE)
Assignee: SILENCE THERAPEUTICS GMBH
C12N15/1137C12N15/111C12N15/113A61K38/00C12N2310/14C12N2310/3183C12N2310/321C12N2310/346C12N2310/53C12N2310/531C12N2320/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,222,092
App. No.
14/578,636
Granted
Dec 29, 2015
Kind
B2
Abstract

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.

Claims (10)

1. A ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides and whereby said second stretch is at least partially identical to a target nucleic acid, whereby the double stranded structure is blunt ended or has an overhang and contains a group of ribonucleic acids on the first or second stretch/strand that has a modification at the 2′-position selected from an amino, fluoro, methoxy, alkoxy or alkyl modification and said group of modified ribonucleic acids on the first or second stretch/strand is flanked on one or both sides by a group of flanking ribonucleic acids having a modification at the 2′-position selected from an amino, fluoro, methoxy, alkoxy or alkyl modification that is different from the modification on said group of ribonucleic acids modified at the 2′-position and the number of ribonucleic acids in the group of modified ribonucleic acids is selected from one to ten ribonucleic acids and the number of ribonucleic acids in the group of flanking ribonucleic acids is selected from one to ten ribonucleic acids.

2. The ribonucleic acid according to claim 1 , wherein the 2′ modification is selected from 2′-O-methyl and 2′-fluoro.

3. The ribonucleic acid according to claim 1 , wherein the double stranded structure is blunt ended on the double stranded structure which is defined by the 3′-end of the first strand and the 5′-end of the second strand.

4. The ribonucleic acid according to claim 1 , wherein at least one of the strands has an overhang of at least one nucleotide at the 3′-end consisting of a ribonucleotide or deoxyribonucleotide.

5. The ribonucleic acid according to claim 1 , wherein the double stranded structure has a length of 17 to 21 nucleotides.

6. The ribonucleic acid according to claim 1 , wherein the ribonucleic acid has an overhang at the 3′-end of the second strand.

7. The ribonucleic acid according to claim 1 , wherein said ribonucleic acid has a double stranded structure that is 15 to 23 nucleotides in length.

8. The ribonucleic acid according to claim 1 , wherein the modifications to the groups of modified ribonucleic acids and the groups of flanking ribonucleic acids are made on internal ribonucleic acids.

9. The ribonucleic acid according to claim 1 , wherein a group of modified ribonucleic acids on the first or second stretch/strand is flanked on both sides by a group of flanking ribonucleic acids having a modification at the 2′-position selected from an amino, fluoro, methoxy, alkoxy or alkyl modification that is different from the modification on said group of modified ribonucleic acids.

10. The ribonucleic acid according to claim 1 , wherein the 2′ modification is selected from 2′-O-methyl and 2′-fluoro.

Assignments (1)
CHANGE OF NAME Recorded Jan 15, 2015
From: SILENCE THERAPEUTICS AG
To: SILENCE THERAPEUTICS GMBH
Reel/Frame 034767/0324 →
Priority Claims (2)
EP 02017601 · Aug 5, 2002 · regional
EP 03008383 · Apr 10, 2003 · regional
Continuity (6)
Continuation 13692178 · Dec 3, 2012
Continuation 12986389 · Jan 7, 2011
Continuation 12200296 · Aug 28, 2008
Continuation 10633630 · Aug 5, 2003
Provisional Application 60402541 · Aug 12, 2002
Related Publication 20150105545A1 · Apr 16, 2015